Research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Although the agreement was rejected in the subsequent October plebiscite, the same month, then-president of Colombia Juan Manuel Santos was awarded the Nobel Peace Prize for his efforts to bring the country's more than 50-year-long civil war to an end. A revised peace deal was signed the following month and submitted to Congress for approval. The House of Representatives unanimously approved the plan on November 30, a day after the Senate gave its backing.
===== Liver ===== In 2022, researchers proposed a new method for printing vascularized human liver tissue. This new method consisted of using a 3D printer capable of holding seven different bioinks, with the ability to switch rapidly between these different bioinks to print different structures and shapes in the liver tissue. Due to the overall complexity of the organ, they were unable to print an entire liver but were still able to successfully print pieces of densely vascularized liver tissue.
== Lawsuits == In November 2010, the parent company of Twin Peaks (Twin Restaurant IP LLC) accused Kevin Laughlin, the owner of Grand Tetons LLC DBA Northern Exposure, of trademark infringement. The lawsuit sought to prevent the opening of Northern Exposure's Fayetteville, Arkansas location after one of Twin Peaks' franchisee noticed a billboard similar to Twin Peaks but advertising Northern Exposure. The lawsuit was settled in the spring of 2011, with Laughlin paying Twin Peaks' legal fees related to the lawsuit. In July 2011, former Hooters executives including CEO and president Coby Brooks, CLO Clay Mingus, Joseph Hummel, Jim Tessmer, Roger Gondek, and the business administrator for the late Robert H. Brooks (founder of Hooters) Patti Frederick left Hooters and formed La Cima Restaurants LLC, a Twin Peaks franchisee. Hooters of America then filed suit against La Cima Restaurants and Joseph Hummel alleging Hummel had electronically sent "more than 500 pages" of Hooters' trade secrets to his private email weeks before he resigned. On May 1, 2012 the Atlanta Business Chronicle reported that Hooters had settled the lawsuit against La Cima and Hummel, with the terms that La Cima and Hummel return or destroy all stolen documents and not use any information on those documents in a competitive manner. On July 8, 2015, the widow of Jesus Delgado Rodriguez (one of the nine bikers killed in the 2015 Waco shootout) filed a lawsuit against Twin Peaks' parent company for negligence.
==== Historic safety concerns ==== In 1952, Kuroya and his colleagues attempted to identify an infectious agent in human tissue samples at Tohoku University Hospital, Sendai, Japan. The samples were taken from the lung of a newborn child that was affected by fatal pneumonia. The primary isolate from the samples was passaged in mice and subsequently in embryonated eggs. The isolated infectious agent was later called Sendai virus, which was used interchangeably with the name "hemagglutinating virus of Japan". Kuroya and his colleagues were convinced that they isolated the virus, which is a new etiological agent for human respiratory infections. Later in 1954, Fukumi and his colleagues at the Japan National Institute of Health put forward an alternative explanation for the origin of the virus. It was suggested that the mice used to passage the virus were infected with the mouse virus. Thus, mouse virus was later transferred to embryonated eggs, isolated and finally named the Sendai virus. This explanation of Fukumi, pointing to the mouse rather than the human origin of the virus, has been supported by numerous scientific data later. The historical aspects of the Sendai virus isolation and controversy behind it are well described in the review. Thus, for some time, it was erroneously assumed that Sendai virus is human disease causing pathogen. The incorrect assumption that the virus was isolated from human infectious material is still reported by Encyclopædia Britannica and by ATCC in the description of the history of the viral isolate Sendai/52.
Sources: en.wikipedia.org
== Aging == Aged mice show a significant reduction of NMNAT1 gene products in the liver (which is the main site of de novo synthesis of NAD+). All NMNAT gene isoform products also decline with age in mice in kidneys, oocytes, and colons.
=== Peptide tags === Short tags on proteins are more commonly called "epitope tags." The tags on this list would fall under that category. "Epitope tagging" is the process of adding a short peptide to a protein such that it can be detected using an antibody specific to that peptide (epitope).
An academic discipline – one with academic departments, curricula and degrees; national and international societies; and specialized journals. A scientific field (a branch of science) – widely recognized category of specialized expertise within science, and typically embodies its own terminology and nomenclature. Such a field will usually be represented by one or more scientific journals, where peer-reviewed research is published. There are several chemistry-related scientific journals. A natural science – one that seeks to elucidate the rules that govern the natural world using empirical and scientific method. A physical science – one that studies non-living systems. A biological science – one that studies the role of chemicals and chemical processes in living organisms. See Outline of biochemistry.
In type 1, MHC class I is not expressed on the cell surface. The defect is caused by defective TAP proteins, not the MHC-I protein. In type 2, MHC class II is not expressed on the cell surface of all antigen presenting cells. Autosomal recessive. The MHC-II gene regulatory proteins are what is altered, not the MHC-II protein itself.
=== Aging === Targeting ferroptosis has emerged as a strategy for mitigating age-related tissue decline. Chronic low-grade systemic inflammation (inflammaging), a hallmark of aging, has been identified as a primary trigger for ferroptotic death in muscle stem cell (MuSC) populations. In mice, long-term administration of the anti-inflammatory compound bindarit, initiated at midlife, suppresses age-associated inflammation and prevents the epigenetic erosion of the Kmt5a–H4K20me1 axis in MuSCs. This preserves the expression of the antioxidant enzyme GPX4, shielding the MuSC pool from iron-dependent lipid peroxidation and maintaining regenerative capacity during aging. More broadly, inhibition of ferroptosis — through radical-trapping antioxidants such as ferrostatin-1 and liproxstatin-1, or through iron chelation — extends lifespan and healthspan in model organisms such as Caenorhabditis elegans. In the context of osteoarthritis, senescent macrophages in skeletal muscle have been shown to promote ferroptosis in myofibers through iron overload and disruption of coenzyme Q10 biosynthesis, contributing to peri-articular muscle atrophy; treatment with CoQ10 attenuates this process.
Sources: en.wikipedia.org
Oral progesterone (Prometrium) metabolizes into neurosteroids including allopregnanolone and pregnanolone which act as potent GABAA receptor positive allosteric modulators. As a result, oral progesterone can dose-dependently produce side effects including dizziness, drowsiness, sedation, somnolence, fatigue, anxiety reduction, euphoria, and cognitive impairment. For this reason, oral progesterone is often taken at night before bed. Oral progesterone taken before bed has been found to improve multiple sleep outcomes in clinical studies. Zuranolone is a synthetic analogue of allopregnanolone that likewise acts as a GABAA receptor positive allosteric modulator but is orally active. It is under development for the treatment of insomnia and is in phase 3 clinical trials for this indication as of September 2025.
=== Mass spectrometry === Pharmacokinetics is often studied using mass spectrometry because of the complex nature of the matrix (often plasma or urine) and the need for high sensitivity to observe concentrations after a low dose and a long time period. The most common instrumentation used in this application is LC-MS with a triple quadrupole mass spectrometer. Tandem mass spectrometry is usually employed for added specificity. Standard curves and internal standards are used for quantitation of usually a single pharmaceutical in the samples. The samples represent different time points as a pharmaceutical is administered and then metabolized or cleared from the body. Blank samples taken before administration are important in determining background and ensuring data integrity with such complex sample matrices. Much attention is paid to the linearity of the standard curve; however it is common to use curve fitting with more complex functions such as quadratics since the response of most mass spectrometers is not linear across large concentration ranges. There is currently considerable interest in the use of very high sensitivity mass spectrometry for microdosing studies, which are seen as a promising alternative to animal experimentation. Recent studies show that Secondary electrospray ionization (SESI-MS) can be used in drug monitoring, presenting the advantage of avoiding animal sacrifice.
In February 2025, Good me held its initial public offering becoming a listed company on the Hong Kong Stock Exchange with the offering raising US$233 million. On its trading debut, its shares dropped 6.4%. The IPO elevated founder Wang Yun'an's personal stake to an estimated HK$8.6 billion (about US$1.2 billion).
Beriplast P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application Fibrogammin P, freeze-dried human coagulation factor XIII concentrate TachoComb, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components Product availability varies from country to country, depending on registration status.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.